Villeurbanne, France

Benoit Joseph

USPTO Granted Patents = 3 

Average Co-Inventor Count = 7.3

ph-index = 1

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 2014-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Benoit Joseph

Introduction

Benoit Joseph is a notable inventor based in Villeurbanne, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of targeted cancer therapies. With a total of 3 patents to his name, his work continues to influence the medical research community.

Latest Patents

Benoit Joseph's latest patents include groundbreaking innovations in antibody drug conjugates. One of his notable inventions is an antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload. This patent provides methods for using ADCs in the treatment of cancer, showcasing his commitment to advancing cancer therapies. Another significant patent involves alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl, which relates to compounds designed to target specific cancer-related proteins.

Career Highlights

Throughout his career, Benoit has worked with esteemed institutions such as Université Claude Bernard Lyon 1 and Università Degli Studi di Milano-Bicocca. His experience in these research environments has allowed him to collaborate with leading experts in the field, further enhancing his contributions to medical science.

Collaborations

Benoit Joseph has collaborated with notable colleagues, including Florence Popowycz and Carlo Gambacorti Passerini. These partnerships have facilitated the exchange of ideas and expertise, leading to innovative solutions in cancer treatment.

Conclusion

Benoit Joseph's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a dedication to improving cancer therapies and advancing medical research. His contributions are invaluable to the ongoing fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…